Physician

Vijaykumar Roy, MD

According to 2025 Medicare claims, Vijaykumar Roy, MD (NPI: 1982688925) practices hematology/oncology in the New York-Jersey City-White Plains, NY-NJ market, with the plurality of this provider's patient population coming from Passaic, NJ. This provider's primary affiliated billing organization is TOTOWA CANCER CENTER (NPI: 1225777808; TIN: 880721476) and primary practice location at 07512-1804. Roy is affiliated with the Vytalize Health 9 ACO LLC (ACO ID: D0313), participating under the REACH model.

Roy's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 263 traditional Medicare patients, billed 135,774 HCPCS/CPT codes, and received $1,714,618 in Medicare payments. The top billing code was 99204 (New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more). Part D data shows 700 prescription claims across 97 beneficiaries totaling $3,617,706 in drug costs, led by Jakafi (Ruxolitinib Phosphate). 2020 DME data shows 33 claims. Open Payments data shows 114 records totaling $3,438. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has changed little. Concurrently, Part D prescription costs did not follow a clear longitudinal pattern. In contrast, DME billing represents a smaller volume and started with an early spike, then settled into a lower baseline, moving from $6,830 to $1,335.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	434	111,275	$1,149,168
2016	434	190,570	$1,529,111
2017	393	216,468	$1,944,572
2018	347	150,053	$1,376,279
2019	310	239,665	$1,546,612
2020	277	224,896	$1,403,016
2021	274	212,611	$1,691,575
2022	279	182,277	$1,665,229
2023	293	170,034	$1,464,558
2024	263	135,774	$1,714,618

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	97	922	$2,010,571
2016	121	1,279	$2,559,180
2017	131	1,519	$4,294,322
2018	118	1,861	$5,736,449
2019	115	2,031	$5,709,082
2020	119	1,517	$4,288,129
2021	106	994	$4,011,603
2022	104	1,004	$3,926,754
2023	100	860	$4,266,892
2024	97	700	$3,617,706

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	186	$7,384
2016	N/R	42	$882
2017	N/R	151	$5,919
2018	N/R	N/R	N/R
2019	N/R	60	$1,277
2020	N/R	33	$710
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99204	New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more	84	84	$134
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	112	498	$106
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	196	982	$74
36415	Insertion of needle into vein for collection of blood sample	243	1,473	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	213	1,118	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Jakafi	Ruxolitinib Phosphate	50	1,500	$1,286,646
Keytruda	Pembrolizumab	36	756	$383,033
Sprycel	Dasatinib	20	600	$363,849
Pomalyst	Pomalidomide	13	364	$273,122
Procrit	Epoetin Alfa	46	1,288	$190,101

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	114	$3,438	E.R. Squibb & Sons, L.L.C.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Vijaykumar Roy, MD?

Tedicare shows public-source Medicare data for Vijaykumar Roy, MD (NPI 1982688925), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Vijaykumar Roy, MD have ACO affiliation data?

Vijaykumar Roy, MD is shown with ACO affiliation data for Vytalize Health 9 ACO LLC (REACH, ACO ID D0313).

What billing organization is linked to Vijaykumar Roy, MD?

Vijaykumar Roy, MD is linked to TOTOWA CANCER CENTER (billing NPI 1225777808) in the available physician profile data.

Does Vijaykumar Roy, MD have Open Payments data?

Vijaykumar Roy, MD has 114 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.